What is Haemonetics's SG&A?

Haemonetics (HAE) reported SG&A of $120.93M in Q1 2026.

How has Haemonetics's SG&A changed year-over-year?

Haemonetics's SG&A increased by 5.0% year-over-year, from $115.14M to $120.93M.

What is the long-term trend for Haemonetics's SG&A?

Over 4 years (2022 to 2026), Haemonetics's SG&A has grown at a 6.8% compound annual growth rate (CAGR), from $340.14M to $442.42M.

Combined selling expenses (sales force, marketing, distribution) and general & administrative costs (management, legal, accounting, facilities) — the broadest opex category.

Haemonetics HAE SG&A

SG&A at other companies

AbbottABT

$3.74B+22.2%

TFX

TeleflexTFX

$226.01M+47.8%

Boston ScientificBSX

$1.78B+11.5%

MedtronicMDT

$3.06B+12.4%

LivaNovaLIVN

$143.57M+11.2%

ICU MedicalICUI

$154.57M-1.7%

Segments

By segment

See full

Hospital$67.03M+7.0%

Plasma$27.27M+11.3%

Blood Center$13.48M-9.6%

Other financials

Income statement

See full

Revenue$346.4M+4.8%

Gross profit$198.2M+2.7%

Operating income$67.4M+14.2%

Net income$44.7M+19.3%

EPS (diluted)$0.95+28.4%

Balance sheet

See full

Cash & equivalents$245.4M-20.0%

Total debt$1.3B-0.7%

Total equity$796.3M-3.0%

Total assets$2.4B-2.2%

Cash flow

See full

Operating cash flow$70.9M-39.1%

CapEx$17.7M+12.9%

Free cash flow$53.3M-47.2%

Valuation

See full

Market cap$3.31B-18.0%

Profitability

See full

Gross margin59%+4.0pp

Operating margin19%+5.9pp

Net margin13.3%+3.8pp

FCF margin19.5%+9.1pp

Returns & leverage

See full

Return on equity19.3%+5.2pp

Debt / equity1.6×0.0×

Current ratio3×+1.3×

Where this comes from

Reported directly by Haemonetics in its filing.

Tagged under the XBRL concept us-gaap:SellingGeneralAndAdministrativeExpense.

The official record: Haemonetics’s 10-K, filed May 20, 2026, on SEC EDGAR. View the filing →

Ask your AI about Haemonetics's sg&a.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Haemonetics's SG&A?: Haemonetics (HAE) reported SG&A of $120.93M in Q1 2026.
How has Haemonetics's SG&A changed year-over-year?: Haemonetics's SG&A increased by 5.0% year-over-year, from $115.14M to $120.93M.
What is the long-term trend for Haemonetics's SG&A?: Over 4 years (2022 to 2026), Haemonetics's SG&A has grown at a 6.8% compound annual growth rate (CAGR), from $340.14M to $442.42M.
What does SG&A mean?: Combined selling expenses (sales force, marketing, distribution) and general & administrative costs (management, legal, accounting, facilities) — the broadest opex category.